Cord blood cells engineered to fight Hard-to-Treat blood cancers

NCT ID NCT05110742

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This study tests a new treatment using immune cells (NK cells) from donated cord blood that are engineered to target a protein called CD5 found on certain cancer cells. The treatment is given after chemotherapy to prepare the body, and the goal is to see if it is safe and effective for people with relapsed or hard-to-treat blood cancers like T-cell lymphoma and leukemia. About 64 participants will take part in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD5-targeted CAR-engineered NK cells from cord blood
What this could lead to: If successful, this could offer a new treatment option for people with blood cancers that have not responded to standard therapies.
What could go wrong: This is an early-phase trial with only 64 participants, so results may not apply to everyone. There are risks of side effects from the chemotherapy and the cell infusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm mantle cell lymphoma mixed phenotype acute leukemia Richter transformation T-cell acute lymphoblastic leukemia T-cell non-Hodgkin lymphoma T-cell prolymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL MALIGNANCY

Contacts and locations

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.